The Food and Drug Administration today said it no longer authorizes the use of hydroxychloroquine or chloroquine as an effective treatment of COVID-19.

FDA cited serious side effects, such as cardiac adverse events, in its decision, stating that it considered results from a large trial and found neither drug to “be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks.” FDA said patients who have already been administered the drugs that were distributed under the original emergency use authorization may continue their use if deemed necessary by physicians.

Related News Articles

Headline
The public health emergency will likely remain in place through 2021, and the administration will give states 60 days’ notice before it decides to terminate…
Headline
The Food and Drug Administration Jan. 21 reissued emergency use authorizations for 10 systems authorized to decontaminate certain N95 respirators used by…
Headline
Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed Friday.  Pfizer said the Phase 3…
Chairperson's File
This year, I look forward to continuing AHA’s Leadership Rounds, short conversations on trending topics with health care leaders from around the country.…
Headline
As COVID-19 surges continue, lessons learned by health systems large and small reveal the importance of teamwork, communication, flexibility, preparation and…
Headline
The Centers for Disease Control and Prevention today reported 10 cases of anaphylaxis, a life-threatening allergic reaction, among the more than 4 million…